Vera Therapeutics, Inc. Accrued Liabilities, Current
Vera Therapeutics, Inc. (VERA) had Accrued Liabilities, Current of $33.75 million as of 2026-06-30, per its 10-Q filed 2026-08-10.
Financial Statements › Balance Sheet › Liabilities › Liabilities, Current › Accounts Payable and Accrued Liabilities, Current › Accrued Liabilities, Current
us-gaap:AccruedLiabilitiesCurrent · last filed 2026-08-10
- 2026-06-30: Accrued Liabilities, Current $33.75M.
- 2026-03-31: Accrued Liabilities, Current $31.24M.
- 2025-12-31: Accrued Liabilities, Current $31.56M; Accrued Liabilities, Current as first filed $31.01M.
- 2025-09-30: Accrued Liabilities, Current $23.46M.
| Period end | Accrued Liabilities, Current | Accrued Liabilities, Current as first filed |
|---|---|---|
| 2026-06-30 | $33.75M 10-Q · filed 2026-08-10 | |
| 2026-03-31 | $31.24M 10-Q · filed 2026-05-07 | |
| 2025-12-31 | $31.56M 10-Q · filed 2026-08-10 | $31.01M 10-K · filed 2026-02-26 |
| 2025-09-30 | $23.46M 10-Q · filed 2025-11-05 | |
| 2025-06-30 | $19.54M 10-Q · filed 2025-08-05 | |
| 2025-03-31 | $11.44M 10-Q · filed 2025-05-07 | |
| 2024-12-31 | $16.22M 10-K · filed 2026-02-26 | |
| 2024-09-30 | $19.99M 10-Q · filed 2024-11-07 | |
| 2024-06-30 | $11.64M 10-Q · filed 2024-08-08 | |
| 2024-03-31 | $7.06M 10-Q · filed 2024-05-10 | |
| 2023-12-31 | $8.75M 10-K · filed 2025-02-28 | |
| 2023-09-30 | $9.80M 10-Q · filed 2023-11-09 | |
| 2023-06-30 | $10.99M 10-Q · filed 2023-08-10 | |
| 2023-03-31 | $15.60M 10-Q · filed 2023-05-11 | |
| 2022-12-31 | $10.96M 10-K · filed 2024-03-27 | |
| 2022-09-30 | $6.22M 10-Q · filed 2022-11-09 | |
| 2022-06-30 | $7.75M 10-Q · filed 2022-08-10 | |
| 2022-03-31 | $10.15M 10-Q · filed 2022-05-16 | |
| 2021-12-31 | $5.93M 10-K · filed 2023-03-28 | |
| 2021-09-30 | $2.71M 10-Q · filed 2021-11-10 | |
| 2021-06-30 | $1.69M 10-Q · filed 2021-08-16 | |
| 2021-03-31 | $1.80M 10-Q · filed 2021-06-24 | |
| 2020-12-31 | $535.00K 10-K · filed 2022-03-28 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Harmony Biosciences Holdings, Inc. (HRMY) | United States | $2.399B | 11.67 |
| uniQure N.V. (QURE) | $2.416B | -4.93 | |
| SELLAS Life Sciences Group, Inc. (SLS) | United States | $2.420B | -91.87 |
| Mineralys Therapeutics, Inc. (MLYS) | United States | $2.353B | -6.82 |
| Nurix Therapeutics, Inc. (NRIX) | United States | $2.457B | -5.39 |
| Viridian Therapeutics, Inc.\DE (VRDN) | United States | $2.342B | -5.38 |
| SUPERNUS PHARMACEUTICALS, INC. (SUPN) | United States | $2.517B | -24.63 |
| Immunome Inc. (IMNM) | United States | $2.538B | -9.45 |
| Disc Medicine, Inc. (IRON) | United States | $2.553B | -11.40 |
| Zai Lab Ltd (ZLAB) | $2.241B | -113.34 |